2015
Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials
Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.Peer-Reviewed Original ResearchConceptsClinical trialsRisk groupsHuman papillomavirus-associated oropharynx cancerHPV-negative OPCPoor-risk subsetTreatment-related morbidityDe-escalation trialsPrognostic risk groupsClinical trial optionsYounger median ageNew treatment strategiesIdeal patient groupNovel therapeutic targetInvasive surgical techniquesDeintensification trialsTreatment deintensificationOropharynx cancerSmoking exposureMetastatic diseaseModality therapyFavorable prognosisMedian ageBetter prognosisSuperior prognosisIntense therapy
2014
Oropharyngeal squamous cell carcinoma treatment
Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment. Current Opinion In Oncology 2014, 26: 252-258. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/cco.0000000000000072.Peer-Reviewed Original ResearchConceptsHigh-risk human papilloma virusOropharyngeal squamous cell carcinomaHPV-unrelated cancersSquamous cell carcinomaNodal stageCell carcinomaTumor stageSquamous cell carcinoma treatmentHPV-unrelated tumorsAdvanced nodal stageRisk of deathCurrent treatment paradigmsHuman papilloma virusParaffin-embedded tissue blocksImportant causative factorAdvanced nodalDistant diseaseHPV statusCurative therapyFavorable prognosisOropharyngeal cancerRetrospective studyPapilloma virusTreatment paradigmRisk groups